Hansoh Pharmaceutical Group Co (HKSE:03692) Additional Paid-In Capital : HK$15,417 Mil(As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Additional Paid-In Capital?

Hansoh Pharmaceutical Group Co's quarterly additional paid-in capital declined from Dec. 2022 (HK$15,558 Mil) to Jun. 2023 (HK$15,417 Mil) but then stayed the same from Jun. 2023 (HK$15,417 Mil) to Dec. 2023 (HK$15,417 Mil).

Hansoh Pharmaceutical Group Co's annual additional paid-in capital increased from Dec. 2021 (HK$0 Mil) to Dec. 2022 (HK$15,558 Mil) but then declined from Dec. 2022 (HK$15,558 Mil) to Dec. 2023 (HK$15,417 Mil).

Hansoh Pharmaceutical Group Co Additional Paid-In Capital Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Additional Paid-In Capital Chart

Hansoh Pharmaceutical Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

15,557.56

15,417.38

Hansoh Pharmaceutical Group Co Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial									-	-	15,557.56	15,417.41	15,417.38

Hansoh Pharmaceutical Group Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Hansoh Pharmaceutical Group Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

3KY:Germany

Address

287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210

Website

https://www.hspharm.com

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Executives

Cen Junda	2307 Founder of a discretionary trust who can infl
Cantrust (far East) Limited	2301 Trustee
Jqc Holding Limited	2201 Interest of corporation controlled by you
Jqc International Limited	2201 Interest of corporation controlled by you
Sun Yuan	2101 Beneficial owner
Harmonia Holding Investing (ptc) Limited	2201 Interest of corporation controlled by you
Stellar Infinity Company Ltd.	2101 Beneficial owner
Sunrise Investment Advisors Limited	2201 Interest of corporation controlled by you
Zhong Huijuan	2307 Founder of a discretionary trust who can infl
Apex Medical Company Ltd.	2101 Beneficial owner

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines